Top Engineering탑엔지니어링
065130 · KOSDAQ · ₩065130 · 탑엔지니어링
₩2,850▲ ₩45 (1.60%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩238B | ₩264B | ₩173B | ₩209B | ₩213B | ₩204B | ₩195B | ₩217B |
| Cost of sales | ₩220B | ₩238B | ₩161B | ₩190B | ₩208B | ₩201B | ₩169B | ₩206B |
| Gross profit | ₩19B | ₩26B | ₩12B | ₩19B | ₩5.4B | ₩2.9B | ₩26B | ₩11B |
| Operating income | ₩5.5B | ₩9B | −₩10B | ₩2B | −₩12B | −₩15B | ₩3.8B | −₩8.8B |
| Net income | −₩4.7B | ₩11B | −₩26B | ₩3.8B | −₩11B | −₩12B | ₩11B | −₩13B |
| Net income to shareholders | ₩4.2B | ₩5.6B | −₩17B | ₩3.8B | −₩11B | −₩12B | ₩11B | −₩13B |
Balance sheet
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total assets | ₩518B | ₩539B | ₩492B | ₩511B | ₩496B | ₩558B | ₩595B | ₩547B |
| Current assets | ₩329B | ₩350B | ₩306B | ₩314B | ₩296B | ₩355B | ₩389B | ₩351B |
| Cash and equivalents | ₩34B | ₩33B | ₩47B | ₩64B | ₩43B | ₩48B | ₩54B | ₩61B |
| Total liabilities | ₩203B | ₩231B | ₩204B | ₩200B | ₩191B | ₩230B | ₩255B | ₩223B |
| Current liabilities | ₩196B | ₩224B | ₩196B | ₩193B | ₩184B | ₩224B | ₩246B | ₩213B |
| Borrowings | ₩69B | ₩68B | ₩57B | ₩61B | ₩68B | ₩76B | ₩71B | ₩75B |
| Total equity | ₩316B | ₩308B | ₩288B | ₩311B | ₩305B | ₩328B | ₩340B | ₩324B |
| Shareholders' equity | ₩166B | ₩162B | ₩153B | ₩169B | ₩171B | ₩182B | ₩193B | ₩191B |
Cash flow
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | ₩14B | −₩26B | −₩3.1B | ₩31B | ₩2.4B | −₩10B | ₩12B | ₩6.3B |
| Capital spending | ₩3.5B | ₩6B | ₩29B | −₩2.8B | −₩3.1B | −₩3.7B | −₩7.7B | −₩2.2B |
| Free cash flow | ₩11B | −₩32B | −₩33B | ₩28B | −₩677M | −₩14B | ₩4.3B | ₩4B |
Consolidated where available. Amounts in won.
Also known as: Top Engineering / 탑엔지니어링 / 065130 / KRX:065130
Source: KRX statistical information